ARTICLE | Clinical News
PL37: Phase IIa started
May 4, 2015 7:00 AM UTC
Pharmaleads began a double-blind, placebo-controlled, European Phase IIa trial to evaluate 200 mg oral PL37 thrice daily plus pregabalin or gabapentin for 4 weeks in 108 patients previously treated wi...